Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of HY-021068 in systemic sclerosis
CTR20244677Phase 2Active
- Sponsor
- Hefei Yigong Pharmaceutical
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing HY-021068 with Placebo (2 arms). Primary endpoint: Change in modified Rodnan Skin Score. Started Jan 2025; status: active.
02
Drugs
piragrel sodium
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on CTR20244677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244677.